209 filings
Page 7 of 11
S-8
iijuyd0
7 Aug 19
Registration of securities for employees
5:31pm
8-K
6j8bjm8bzvds38
7 Aug 19
Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress
4:39pm
8-K
ujjq 5r499
2 Jul 19
Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome
8:05am
8-K
ho4zic 9sg
27 Jun 19
Regulation FD Disclosure
12:04pm
8-K
akft0ka paufnqmel
27 Jun 19
Other Events
8:05am
8-K
be09y3ezm2acpz
18 Jun 19
Other Events
8:10am
8-K/A
ua78b
17 Jun 19
Entry into a Material Definitive Agreement
4:30pm
8-K
thbcab
10 Jun 19
Submission of Matters to a Vote of Security Holders
5:26pm
8-K
m9f6o
15 May 19
Entry into a Material Definitive Agreement
5:29pm
8-K
8dqr4rl 6zsvndy1160
7 May 19
Ovid Therapeutics Reports First Quarter 2019 Financial Results
8:05am
DEFA14A
1fnfv7sk7xhpd8y6h
24 Apr 19
Additional proxy soliciting materials
5:30pm
8-K/A
lbjgb6whg4v6s3ns
28 Mar 19
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline
12:27pm
8-K
zve8t3
28 Mar 19
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline
8:02am
8-K
vd212g 49
21 Mar 19
Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary
8:02am
8-K
ekh8b
11 Mar 19
Regulation FD Disclosure
2:51pm
8-K
635ahcrq0bwemqe z05o
7 Mar 19
Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
4:13pm